Jul 7, 2026 07:18AM
Jun 26, 2026 10:02AM
Jun 26, 2026 10:02AM
Jun 26, 2026 09:05AM
Jun 26, 2026 09:05AM
May 13, 2026 04:15AM
May 12, 2026 04:05PM Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026 07:15AM
Apr 22, 2026 09:02AM
Apr 22, 2026 09:00AM
Mar 13, 2026 07:30AM
Mar 12, 2026 04:01PM
Mar 12, 2026 09:02AM
Mar 12, 2026 09:00AM Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
Mar 10, 2026 10:37AM
Mar 10, 2026 10:05AM
Mar 10, 2026 09:25AM
Mar 10, 2026 09:25AM
Feb 24, 2026 09:00AM
Jan 20, 2026 09:15AM
Jan 20, 2026 09:15AM Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
Jan 16, 2026 07:11AM
Jan 14, 2026 06:57AM
Dec 21, 2025 04:00AM
Sep 18, 2025 05:08AM
Jul 18, 2025 01:43PM
Jun 26, 2025 02:13AM
Jun 24, 2025 12:29PM H.C. Wainwright said 'Ignore the Noise' on Capricor Therapeutics (CAPR) and Buy
Jun 24, 2025 09:01AM
Jun 24, 2025 09:00AM
Jun 23, 2025 06:43AM
Jun 23, 2025 04:45AM
Jun 17, 2025 09:01AM
Jun 17, 2025 09:00AM
Jun 16, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Jun 13, 2025 11:28AM
Jun 11, 2025 01:03PM
Jun 11, 2025 09:25AM
Jun 11, 2025 09:25AM
May 13, 2025 04:05PM
May 5, 2025 08:06AM
May 5, 2025 08:00AM Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Mar 20, 2025 08:17AM
Mar 19, 2025 04:05PM
Mar 17, 2025 09:25AM
Mar 17, 2025 09:25AM
Mar 10, 2025 09:13AM
Mar 5, 2025 06:48AM
Mar 4, 2025 07:02AM Capricor Therapeutics (CAPR) Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Mar 4, 2025 07:00AM

15,536 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All